4564 OncoTherapy Science, Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4564

TSE Growth

OncoTherapy Science, Inc.

JPY

(0.00%)

Apr 14, 1:14 pm JST

0.16

USD

Apr 14, 12:14 am EDT

Result

ー

PTS

outside of trading hours

24.4

Apr 14, 1:26 pm JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	332	-1,637	-1,639	-1,561	-8.9	0	May 7, 2021	J-GAAP
Mar, 2022	1,153	-2,052	-2,071	-2,571	-13.7	0	May 6, 2022	J-GAAP
Mar, 2023	1,134	-1,106	-1,133	-1,118	-5.8	0	May 12, 2023	J-GAAP
Mar, 2024	610	-1,120	-1,136	-1,288	-6.1	0	May 10, 2024	J-GAAP
Mar, 2025 Guidance	ー	ー	ー	ー	－	0	May 10, 2024	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 10, 2019	ー	ー	ー	ー	0	J-GAAP
- - - - Results	May 8, 2020	316	-2,189	-2,197	-2,238	0	J-GAAP
Mar, 2021	May 8, 2020	Available in future release
Results	May 7, 2021
Mar, 2022	May 7, 2021
Results	May 6, 2022
Mar, 2023	May 6, 2022
Results	May 12, 2023
Mar, 2024	May 12, 2023
Results	May 10, 2024
Mar, 2025	May 10, 2024	ー	ー	ー	ー	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2002	0	－	Available in future release
Mar, 2003	975	－
Mar, 2004	1,578	+61.8
Mar, 2005	1,580	+0.1
Mar, 2006	1,164	-26.3
Mar, 2007	804	-30.9
Mar, 2008	1,972	+145.3
Mar, 2009	3,327	+68.7
Mar, 2010	5,257	+58.0
Mar, 2011	5,361	+2.0
Mar, 2012	6,223	+16.1
Mar, 2013	3,277	-47.3
Mar, 2014	1,017	-69.0
Mar, 2015	769	-24.4
Mar, 2016	266	-65.4
Mar, 2017	286	+7.5
Mar, 2018	211	-26.2
Mar, 2019	280	+32.7
Mar, 2020	316	+12.9
Mar, 2021	332	+5.1
Mar, 2022	1,153	+247.3
Mar, 2023	1,134	-1.6
Mar, 2024	610	-46.2
Mar, 2025 Guidance	ー	-100.0	ー	+100.0	ー	+100.0	－	+100.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	1,134	-1,106	-98	-83.65	-53.29	0.54	-5.8
Mar, 2024	610	-1,120	-184	-243.94	-108.33	0.51	-6.1
Mar, 2025 Guidance	ー	ー	ー	ー	ー	ー	－

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	6,223	1,184	1,255	726	7.0
Fiscal Year	Mar, 2012	Mar, 2012	Mar, 2012	Mar, 2012	Mar, 2012

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	913	-1,104	-1,119	-1,342	-7.2	0	May 6, 2022	J-GAAP
Oct - Mar, 2022	620	-488	-490	-505	-2.6	0	May 12, 2023	J-GAAP
Oct - Mar, 2023	254	-426	-428	-578	-2.7	0	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	ー	ー	ー	ー	－	0	May 10, 2024	J-GAAP
YoY	－	－	－	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	-2,052	-2,540	-2,073	-467	1,478	1,836	68.38	J-GAAP
Mar, 2023	-1,106	-814	-794	-20	95	1,117	73.92	J-GAAP
Mar, 2024	-1,120	-1,260	-1,227	-33	671	527	60.78	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	699	-904	-928	-913	-4.7	ー	Feb 10, 2023	J-GAAP
Apr - Dec, 2023	466	-972	-986	-987	-4.7	ー	Feb 9, 2024	J-GAAP
Apr - Dec, 2024	563	-698	-716	-717	-2.8	ー	Feb 7, 2025	J-GAAP
YoY	+20.8%	+28.2%	+27.4%	+27.4%	+40.6%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2023	435	-202	-205	-205	-1.1	-46.4	May 12, 2023	J-GAAP
Apr - Jun, 2023	148	-386	-397	-400	-2.0	-260.8	Aug 10, 2023	J-GAAP
Jul - Sep, 2023	208	-308	-311	-310	-1.5	-148.1	Nov 10, 2023	J-GAAP
Oct - Dec, 2023	110	-278	-278	-277	-1.3	-252.7	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	144	-148	-150	-301	-1.4	-102.8	May 10, 2024	J-GAAP
Apr - Jun, 2024	100	-290	-302	-302	-1.3	-290.0	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	125	-241	-243	-243	-1.0	-192.8	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	338	-167	-171	-172	-0.7	-49.4	Feb 7, 2025	J-GAAP
YoY	+207.3%	+39.9%	+38.5%	+37.9%	+48.9%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2020	155	+369.7	Available in future release
Apr - Jun, 2020	41	-25.5
Jul - Sep, 2020	59	+20.4
Oct - Dec, 2020	60	+5.3
Jan - Mar, 2021	172	+11.0
Apr - Jun, 2021	93	+126.8
Jul - Sep, 2021	147	+149.2
Oct - Dec, 2021	95	+58.3
Jan - Mar, 2022	818	+375.6
Apr - Jun, 2022	385	+314.0
Jul - Sep, 2022	129	-12.2
Oct - Dec, 2022	185	+94.7
Jan - Mar, 2023	435	-46.8
Apr - Jun, 2023	148	-61.6
Jul - Sep, 2023	208	+61.2
Oct - Dec, 2023	110	-40.5
Jan - Mar, 2024	144	-66.9
Apr - Jun, 2024	100	-32.4
Jul - Sep, 2024	125	-39.9
Oct - Dec, 2024	338	+207.3	-167	+39.9	-171	+38.5	-0.7	+46.2

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	4,766	3,331	3,387	2,900	27.8
Fiscal Year	Mar, 2012	Mar, 2012	Mar, 2012	Mar, 2012	Mar, 2012

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	9.84	70.6	2,685	1,896	-23,686	ー	May 6, 2022	J-GAAP
Mar, 2023	4.04	51.4	1,511	777	-24,804	ー	May 12, 2023	J-GAAP
Mar, 2024	1.28	32.2	867	279	-26,092	ー	May 10, 2024	J-GAAP
Apr - Dec, 2024	ー	61.4	1,232	756	-26,810	ー	Feb 7, 2025	J-GAAP

OncoTherapy Science, Inc.(4564) Financial Results